125 related articles for article (PubMed ID: 12120908)
1. Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study.
Ringe JD; Setnikar I
Rheumatol Int; 2002 May; 22(1):27-32. PubMed ID: 12120908
[TBL] [Abstract][Full Text] [Related]
2. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
Reginster JY; Meurmans L; Zegels B; Rovati LC; Minne HW; Giacovelli G; Taquet AN; Setnikar I; Collette J; Gosset C
Ann Intern Med; 1998 Jul; 129(1):1-8. PubMed ID: 9652994
[TBL] [Abstract][Full Text] [Related]
3. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
[TBL] [Abstract][Full Text] [Related]
4. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
Alexandersen P; Riis BJ; Christiansen C
J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
[TBL] [Abstract][Full Text] [Related]
5. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
Ringe JD; Kipshoven C; Cöster A; Umbach R
Osteoporos Int; 1999; 9(2):171-8. PubMed ID: 10367046
[TBL] [Abstract][Full Text] [Related]
6. Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial.
Reid IR; Cundy T; Grey AB; Horne A; Clearwater J; Ames R; Orr-Walker BJ; Wu F; Evans MC; Gamble GD; King A
J Clin Endocrinol Metab; 2007 Jul; 92(7):2446-52. PubMed ID: 17440020
[TBL] [Abstract][Full Text] [Related]
7. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study.
Guaydier-Souquières G; Kotzki PO; Sabatier JP; Basse-Cathalinat B; Loeb G
Osteoporos Int; 1996; 6(2):171-7. PubMed ID: 8704358
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study.
Ringe JD; Dorst A; Faber H; Kipshoven C; Rovati LC; Setnikar I
Rheumatol Int; 2005 May; 25(4):296-300. PubMed ID: 15770482
[TBL] [Abstract][Full Text] [Related]
9. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
Meunier PJ; Sebert JL; Reginster JY; Briancon D; Appelboom T; Netter P; Loeb G; Rouillon A; Barry S; Evreux JC; Avouac B; Marchandise X
Osteoporos Int; 1998; 8(1):4-12. PubMed ID: 9692071
[TBL] [Abstract][Full Text] [Related]
10. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride.
Delmas PD; Dupuis J; Duboeuf F; Chapuy MC; Meunier PJ
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S143-7. PubMed ID: 2339624
[TBL] [Abstract][Full Text] [Related]
11. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate.
Ringe JD; Dorst A; Kipshoven C; Rovati LC; Setnikar I
Osteoporos Int; 1998; 8(1):47-52. PubMed ID: 9692077
[TBL] [Abstract][Full Text] [Related]
12. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.
Gutteridge DH; Holzherr ML; Retallack RW; Price RI; Will RK; Dhaliwal SS; Faulkner DL; Stewart GO; Stuckey BG; Prince RL; Criddle RA; Drury PJ; Tran L; Bhagat CI; Kent GN; Jamrozik K
Calcif Tissue Int; 2003 Jul; 73(1):33-43. PubMed ID: 14506952
[TBL] [Abstract][Full Text] [Related]
14. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
Harris ST; Eriksen EF; Davidson M; Ettinger MP; Moffett AH; Baylink DJ; Crusan CE; Chines AA
J Clin Endocrinol Metab; 2001 May; 86(5):1890-7. PubMed ID: 11344179
[TBL] [Abstract][Full Text] [Related]
15. Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents.
Wimalawansa SJ
J Clin Densitom; 2000; 3(2):187-201. PubMed ID: 10871912
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
Gutteridge DH; Stewart GO; Prince RL; Price RI; Retallack RW; Dhaliwal SS; Stuckey BG; Drury P; Jones CE; Faulkner DL; Kent GN; Bhagat CI; Nicholson GC; Jamrozik K
Osteoporos Int; 2002; 13(2):158-70. PubMed ID: 11908491
[TBL] [Abstract][Full Text] [Related]
17. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
[TBL] [Abstract][Full Text] [Related]
18. Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate.
Meys E; Terreaux-Duvert F; Beaume-Six T; Dureau G; Meunier PJ
Osteoporos Int; 1993 Dec; 3(6):322-9. PubMed ID: 8292843
[TBL] [Abstract][Full Text] [Related]
19. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
